RxDoctor Payments DataLook up a doctor →

Jeffrey Satinover

Psychiatry · Danbury, CTNPI 1770611717

Payments from drug & device makers

$16,424in general payments, 2019–2025

Across 874 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Vanda Pharmaceuticals Inc.$1K
  • Corium, LLC$999
  • Avanir Pharmaceuticals, Inc.$900
  • plus $8K from 28 others

What the payments were for

  • Food & beverage$16,418100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,424 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$273,060
Medicare patients
170
Services billed
1,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide45$57,051
FanaptIloperidone11$28,117
RexultiBrexpiprazole13$21,986
VyvanseLisdexamfetamine Dimesylate38$20,482
BelsomraSuvorexant21$19,010
SunosiSolriamfetol Hcl22$18,091
VraylarCariprazine Hcl13$15,022
Vilazodone Hcl40$14,893
AuvelityDextromethorphan Hbr/Bupropion16$14,404
DayvigoLemborexant26$9,556
Bupropion XlBupropion Hcl400$9,262
Lurasidone Hcl58$8,580
Quetiapine Fumarate293$7,079
Aripiprazole150$6,567
Asenapine Maleate14$6,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$1,754$77,53483 claims
Axsome Therapeutics, Inc.Sunosi, Auvelity$597$32,49638 claims
Vanda Pharmaceuticals Inc.Fanapt$1,036$28,11711 claims
Otsuka America Pharmaceutical, Inc.Rexulti$631$21,98613 claims
MerckBelsomra$271$19,01021 claims
AbbVieVraylar$2,294$15,02213 claims
Eisai Inc.Dayvigo$488$9,55626 claims
Corium, LLCAzstarys$999$4,59711 claims
Almatica Pharma LLCSertraline Hcl$53$4,037240 claims
Lilly USA, LLCOlanzapine$12$1,93455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →